Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites

Introduction: The polymorphic enzyme cytochrome P450 2D6 (CYP2D6) catalyzes a major step in the bioactivation of tamoxifen. Genotyping of clinically relevant CYP2D6 alleles and subsequent dose adjustment is a promising approach to individualize breast cancer therapy. The aim of this study was to inv...

Full description

Bibliographic Details
Main Authors: Zahra Khalaj, Zohreh Baratieh, Parvaneh Nikpour, Matthias Schwab, Elke Schaeffeler, Fariborz Mokarian, Hossein Khanahmad, Rasoul Salehi, Thomas E. Mürdter, Mansoor Salehi
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-05-01
Series:Frontiers in Pharmacology
Subjects:
CYP2D6
dose
endoxifen
genotype
metabolite
tamoxifen
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00530/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.00530/full

Similar Items